Chinese VCs Seek $35 Billion in New Dollar Funds as AI Wins Revive Foreign Interest
For three years, the market for Chinese venture capital denominated in U.S. dollars was, in the words of one adviser, "starved of capital." Now it is stirring back to life. Chinese VC firms are marketing at least 60 new dollar-denominated funds targeting roughly $35 billion in fresh commitments — a cautious reopening of international capital into a startup ecosystem that global investors had all but written off, driven above all by the sudden credibility of China's artificial intelligence sector.
The scale of the turnaround is best measured against how far the market fell. According to Preqin data cited by the Financial Times, more than 1,100 China-focused funds raised about $150 billion in 2022. By 2025, just 97 funds managed to close a combined $13.6 billion. The new fundraising push, reported in early August 2026 and built on data from advisory firm Asante Capital, includes roughly 40 venture funds among the 60-plus vehicles now being shopped to limited partners.
What changed: AI turned skepticism into a thesis
The catalyst is not a broad thaw in U.S.-China relations — those remain frosty — but a specific and hard-to-ignore fact: Chinese AI companies keep shipping frontier-level results despite Washington's export controls on advanced chips. Breakthroughs from DeepSeek and Moonshot AI, alongside rapid progress in robotics and a string of successful public listings, have reframed the investment case.
DeepSeek closed its first external funding round in June 2026, raising more than 50 billion yuan (about $7.4 billion) at a valuation exceeding $50 billion, and is now reportedly chasing a fresh round at a valuation approaching $70 billion. Moonshot AI, maker of the Kimi models, raised roughly $3.9 billion across two rounds in the first half of the year, including a $2 billion round led by Meituan's Longzhu fund with China Mobile and CPE participating. For LPs, the narrative crystallized: Chinese models are cost-competitive, and Chinese tech now looks like a viable hedge against a U.S. market where AI valuations have run hot.
Crucially, the returns are becoming real rather than theoretical. Early backers of listed AI developers MiniMax and Zhipu — including Yunqi Partners, Future Capital, IDG Capital, Qiming and Luminous Ventures — have converted IPO gains into the currency of new fundraising: a track record. Limited partners increasingly treat early conviction in large-language-model companies as proof of managerial judgment in the AI era.
Who is raising
The roster of firms in the market reads like a who's-who of Chinese venture capital. Hongshan (known as HSG, the former Sequoia China) has told LPs it will launch a new early-stage dollar fund this year alongside a renminbi vehicle. IDG Capital is planning a growth fund of about $2 billion plus a renminbi fund. Matrix Partners China and Future Capital are also marketing new vehicles, while ZhenFund and Qiming have recently closed funds. Future Capital's new fund is expected to top $200 million, targeting AI hardware and scientific applications such as drug discovery.
A new generation of smaller, specialist managers is emerging in parallel, often raising sub-$100 million funds focused on narrow niches like robotics supply chains or AI agents. Nebulon Ventures, led by Baidu Ventures alumnus Yongteng Wen, is raising $60 million and pitching itself as part of that younger cohort. Deeptech-focused firms Vitalbridge and T-Capital are reported to be nearing the close of dollar funds backed by international LPs.
The geopolitics of AI capital
The reopening exposes a widening gap between political posture and capital flows. U.S. institutional investors — pensions and endowments — remain largely on the sidelines, constrained by Biden-era restrictions on investment in sensitive Chinese technologies and wary of the reputational risk. Into that vacuum have stepped European and Middle Eastern LPs, who have shown greater appetite, though it is not yet clear they can replace the American money that once anchored these funds.
That dynamic is the real story beneath the headline number. Export controls were designed, in part, to keep Chinese firms off the AI frontier and to make the sector uninvestable for global capital. DeepSeek and Moonshot have undercut the first premise, and the money now chasing them is undercutting the second — just with a different passport. Valuations that sit well below U.S. comparables only sharpen the pitch.
Ricardo Felix, Asia-Pacific head at Asante Capital, has been careful to temper the enthusiasm, telling the Financial Times that the current activity amounts to a "selective reopening" of dollar fundraising rather than a full-scale resurgence. The caveats are substantial. Fundraising targets remain far below the 2020-2021 peak. Many funds have yet to return capital to LPs even as IPO windows reopen. And the sheer number of firms rushing to raise simultaneously raises the question of whether demand can absorb them all.
What to watch
Three signals will tell whether $35 billion is a genuine turning point or a burst of AI-fueled optimism. First, closings: how many of these 60-plus funds actually hit their targets, and how quickly. Second, the LP mix — whether European and Gulf money can genuinely offset absent U.S. capital, or whether the pool proves too shallow. Third, DeepSeek's next round and any move toward an IPO by Moonshot, which would test whether paper gains translate into distributions that keep foreign LPs engaged. For now, the appetite is real but discerning. The boom years, when investors queued for oversubscribed Chinese funds, are not back — and few in the market expect them to be.